Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Cwm LLC

Cwm LLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 77.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 1,530 shares of the biopharmaceutical company’s stock after acquiring an additional 668 shares during the period. Cwm LLC’s holdings in Halozyme Therapeutics were worth $88,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares in the last quarter. Fifth Third Bancorp boosted its position in Halozyme Therapeutics by 2.4% during the 2nd quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 261 shares during the period. Private Advisor Group LLC boosted its position in Halozyme Therapeutics by 1.8% during the 2nd quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock worth $1,191,000 after acquiring an additional 412 shares during the period. Retirement Systems of Alabama boosted its position in Halozyme Therapeutics by 0.3% during the 1st quarter. Retirement Systems of Alabama now owns 165,881 shares of the biopharmaceutical company’s stock worth $6,748,000 after acquiring an additional 436 shares during the period. Finally, First Hawaiian Bank boosted its position in Halozyme Therapeutics by 10.5% during the 2nd quarter. First Hawaiian Bank now owns 5,571 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 530 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group lifted their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. Benchmark restated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a report on Friday. Finally, Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.44.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $49.25 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $32.95 and a twelve month high of $65.53. The firm has a market cap of $6.24 billion, a P/E ratio of 19.09, a PEG ratio of 0.50 and a beta of 1.27. The company has a 50 day moving average of $57.99 and a 200 day moving average of $51.58. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. Halozyme Therapeutics’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.68 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total transaction of $525,800.00. Following the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $35,583,199.52. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $35,583,199.52. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 89,881 shares of company stock valued at $5,169,834. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.